Table 5

Response of NHL to chemotherapy in CMMR-D

Author/yearType of lymphomaGene defectAge (years)ChemotherapyOther therapyResponseOutcome/status
Ostergaard/2005T cell NHLMSH610YesNoPartial remissionDied from progression 6 months later
Scott/2007T cell NHLMSH22.5BFM-NHL95 & MRC ALL 97/99NoPartial remissionRecurrence 2 weeks after completion of chemotherapy
2.5MRC ALL R3 protocol (minus cyclophosphamide) etoposideTotal body RT, peripheral blood stem cell transplantationComplete remissionAlive, 6 years
Kratz/2008T cell NHLPMS26BFM-NHL95NoComplete remissionAlive, 16 years
Kruger/2008T cell NHLPMS210Euro-LB 02NoComplete remissionAlive
Peters/2009T cell NHLMSH68Children's oncology group protocol A 5971NoComplete remissionRelapse 9 months after diagnosis
8–9ifosfamide, cisplatin, etoposide, nelarabineRadiotherapyResistantProgression, died at age 9 years
Ripperger/2010T cell NHLMSH66BFM-NHL95NoNot specifiedRelapse 6 months after completion of chemotherapy
ALL REZ BFM 2002Haematopoietic stem cell transplantationComplete remissionAlive 7 years later
Ilencikova/2011T cell NHLMSH611Euro-LB 2002Good responseDied from BT <1 year
Baas/2013T cell NHLMLH15.5Children's oncology group-A5971NoDied from staphylococcal sepsis
Baas/2013B cell NHLPMS29SNWLK-94NoComplete remission11years, 6 months: T cell NHL
Euro LB-02 protocolNoNot reported
Baas/2013T cell NHLPMS25.5Euro LB-02No“Initially good response”Died 9 months later from sepsis during bone marrow aplasia
  • ALL, acute lymphoblastic leukaemia; CMMR-D, constitutional mismatch repair-deficiency; NHL, non-Hodgkin lymphoma.